HBsAg is the hallmark of HBV infection and is the first serological marker to appear in acute hepatitis B. Most patients recovering from acute hepatitis B clear HBsAg within 4-6 months after onset ...

In HIV-infected adolescents, the degree of immunosuppression is correlated with persistence of HBV replicative markers ... risk for infection with hepatitis B virus (HBV) and hepatitis C virus ...

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

Chronic hepatitis B (CHB) remains a significant global health ... Virological response (VR), ALT normalization rates, renal function markers, and lipid profiles were monitored.

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Non-immune hepatitis B status was defined by absence of all hepatitis B markers. The primary outcome for the study was the proportion of subjects with a positive QuantiFERON-TB Gold assay result.

Cox proportional hazards models were used to calculate the HRs of developing HCC after seroclearance of HBV markers. Results The HR (95% CI) of developing HCC after seroclearance of HBeAg, HBV DNA and ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...